Peter Rahmer - 27 Jun 2024 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Chief Corporate Development Officer
Signature
/s/ Thomas Catinazzo, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
27 Jun 2024
Net transactions value
+$10,145
Form type
4
Filing time
01 Jul 2024, 16:41:56 UTC
Previous filing
05 Jun 2024
Next filing
31 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Sale $1,534 -245 -0.06% $6.26 432,180 27 Jun 2024 Direct F1, F2
transaction RLAY Common Stock Award $11,678 +2,108 +0.49% $5.54 434,288 30 Jun 2024 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on June 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F2 Includes 383,442 shares underlying RSUs.
F3 The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
F4 In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 28, 2024.

Remarks:

Chief Corporate Development Officer